In a 48-week phase 2 trial of people with obesity or overweight and one weight-related comorbidity without type 2 diabetes, the mean percent weight change was 7.3%, 10.5%, 13.8%, 17.5%, with weekly eloralintide 1 mg, 3 mg, 6 mg, and 9 mg, respectively, compared to 2.3% with placebo (Table 1) [40]
GLP-1 RAs for smoking cessation may mitigate weight gain
Hypoglycaemia risk is generally low with Mounjaro monotherapy due to its glucose-dependent mechanism of action
Pharmacotherapy represents a relatively new approach to the management of AIWG and obesity [16]
Yakovleva O, Bogatova K, Mukhtarova R, Yakovlev A, Shakhmatova V, Gerasimova E, Ziyatdinova G, Hermann A, Sitdikova G (2020) Hydrogen sulfide alleviates anxiety, motor, and cognitive dysfunctions in rats with maternal hyperhomocysteinemia via mitigation of oxidative stress